Market News

Cheyne Capital Management Uk Llp Upped Vanda Pharmaceuticals (VNDA) Position By $750,000; 2 Analysts Are Bullish Wajax (TSE:WJX) Last Week

Cheyne Capital Management Uk Llp increased Vanda Pharmaceuticals Inc (VNDA) stake by 208.33% reported in 2017Q4 SEC filing. Cheyne Capital Management Uk Llp acquired 50,000 shares as Vanda Pharmaceuticals Inc (VNDA)’s stock rose 9.54%. The Cheyne Capital Management Uk Llp holds 74,000 shares with $1.13 million value, up from 24,000 last quarter. Vanda Pharmaceuticals Inc now has $888.49 million valuation. The stock decreased 0.58% or $0.1 during the last trading session, reaching $17.05. About 107,521 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 15.63% since May 17, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.

Among 5 analysts covering Wajax Corp (TSE:WJX), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Wajax Corp had 18 analyst reports since August 10, 2015 according to SRatingsIntel. TD Securities downgraded the stock to “Hold” rating in Tuesday, December 13 report. The firm earned “Outperform” rating on Wednesday, November 16 by Scotia Capital. The company was upgraded on Wednesday, March 8 by TD Securities. The rating was upgraded by TD Securities to “Buy” on Wednesday, November 2. The firm has “Sector Perform” rating given on Friday, October 28 by Scotia Capital. The stock of Wajax Corporation (TSE:WJX) earned “Buy” rating by Desjardins Securities on Monday, August 10. The rating was maintained by BMO Capital Markets on Wednesday, November 2 with “Market Perform”. The stock of Wajax Corporation (TSE:WJX) earned “Market Perform” rating by Raymond James on Monday, August 10. See Wajax Corporation (TSE:WJX) latest ratings:

Investors sentiment decreased to 1.17 in 2017 Q4. Its down 0.26, from 1.43 in 2017Q3. It worsened, as 19 investors sold VNDA shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 39.77 million shares or 2.28% more from 38.89 million shares in 2017Q3 were reported. Swiss Bancorporation reported 69,500 shares. Citigroup has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). 379,829 are held by Jpmorgan Chase Communication. Manufacturers Life Insur The accumulated 34,198 shares. Goldman Sachs Group invested in 189,858 shares or 0% of the stock. Palo Alto Investors Lc has 2.72% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 4.16M shares. Cadence Cap Management Ltd Liability reported 109,074 shares. 797,531 were accumulated by Great Point Ltd Com. University Of Notre Dame Du Lac holds 202,230 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 1,527 shares or 0% of all its holdings. Secor LP owns 0.08% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 127,277 shares. International Grp Inc accumulated 29,666 shares. Moreover, Deutsche Comml Bank Ag has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 112,712 shares. Foundry Ptnrs Ltd Co holds 77,160 shares or 0.05% of its portfolio. Clarivest Asset Ltd Liability Corp, California-based fund reported 45,999 shares.

Cheyne Capital Management Uk Llp decreased Nasdaq Inc (NASDAQ:NDAQ) stake by 198,608 shares to 4,305 valued at $331,000 in 2017Q4. It also reduced Ishares Tr (Prn) (IBB) stake by 705,853 shares and now owns 21,300 shares. Synergy Pharmaceuticals Del (NASDAQ:SGYP) was reduced too.

More news for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were recently published by: Seekingalpha.com, which released: “Vanda Pharmaceuticals’ (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results – Earnings Call Transcript” on May 03, 2018. Globenewswire.com‘s article titled: “Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals …” and published on May 10, 2018 is yet another important article.

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 24 analyst reports since September 2, 2015 according to SRatingsIntel. Oppenheimer maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Monday, October 30 with “Outperform” rating. The firm has “Buy” rating given on Monday, March 5 by Oppenheimer. The rating was maintained by JMP Securities on Friday, August 26 with “Market Outperform”. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Thursday, October 19 by Piper Jaffray. The firm has “Buy” rating given on Wednesday, October 21 by Brean Capital. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Jefferies on Monday, June 26. The firm has “Buy” rating by Oppenheimer given on Monday, January 8. Oppenheimer maintained the stock with “Buy” rating in Sunday, November 12 report. As per Tuesday, February 13, the company rating was maintained by Jefferies. The firm earned “Buy” rating on Wednesday, September 2 by Piper Jaffray.

Since January 2, 2018, it had 0 insider buys, and 8 insider sales for $4.89 million activity. 60,966 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares with value of $1.14M were sold by Polymeropoulos Mihael Hristos. $68,473 worth of stock was sold by Gulino Richard L. on Wednesday, February 28. $159,712 worth of stock was sold by Kelly James Patrick on Wednesday, February 28. Birznieks Gunther sold $130,777 worth of stock.

Wajax Corporation engages in the sale, rental, and after-sale parts and service support of mobile equipment, power systems, and industrial components. The company has market cap of $510.68 million. The firm operates through Equipment, Power Systems, and Industrial Components divisions. It has a 16.67 P/E ratio. The Equipment segment distributes, modifies, and services equipment, such as excavators, articulated dump trucks, lift trucks, mining trucks and shovels, forest harvesting equipment, utility equipment, loader backhoes, container handlers, cranes, skid steer loaders, and wheel loaders.

The stock increased 0.08% or $0.02 during the last trading session, reaching $25.5. About 18,702 shares traded. Wajax Corporation (TSE:WJX) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *